Research paper on positive results treatment for advanced breast cancer with the fetal estrogen estetrol (E4) has been accepted for publication in the Journal of Cancer Research and Clinical Oncology

Pantarhei Oncology proudly announces that its paper ‘Tumor Suppression, Dose Limiting Toxicity and Wellbeing with the Fetal Estrogen Estetrol (E4) in patients with advanced breast cancer’ has been accepted for publication in the Journal of Cancer Research and Clinical Oncology after comprehensive review. The Journal of Cancer Research and Clinical Oncology is an international peer-reviewed scientific journal in the field of oncology.

The research paper states that treating postmenopausal women diagnosed with advanced breast cancer can be treated safely with high doses of E4. All 12 patients enrolled had progressive, heavily pre-treated advanced breast cancer. No treatment-related serious adverse events  or doses of limiting toxicity (DLTs) occurred during the first 4 weeks of E4 treatment allowing further investigation of all three doses. Five of nine patients completing 12 weeks of E4 treatment showed objective anti-tumor effects and six of nine patients reported improved wellbeing.

Schmidt_et_al-2020-Journal_of_Cancer_Research_and_Clinical_Oncology

Review paper on the risk of breast cancer in relation to gender, breast development and gonadal function published in JCEM

The Journal of Clinical Endocrinology & Metabolism has accepted the manuscript “Breast Cancer and Major Deviations of Genetic and Gender-related Structures and Function” by Herjan J.T. Coelingh Bennink, Jan F.M. Egberts, Jan A. Mol, Kit C.B. Roes, Paul J. van Diest for publication. The review reports of the risk of breast cancer (BC) in relation to gender, breast development and gonadal function in eight populations with different genetic conditions. Main three conclusions are: 1) the presence of an Y chromosome protects against the development of BC; 2) Without menstrual cycles, BC hardly occurs with an incidence comparable to males; 3) BC has been reported only once in genetic females with the Mayer-Rokitansky-Küster-Hauser syndrome, who have normal breasts and ovulating ovaries with normal levels of estrogens and progesterone.

For more information, please read the abstract.

 

 

Review paper on the use of high-dose estrogens (HDE) for the treatment of breast cancer

Review paper on the use of high-dose estrogens (HDE) for the treatment of breast cancer

Estrogens are known to stimulate the growth of breast cancer, whereas on the other hand estrogens are an effective treatment for this disease. The fact that estrogens can effectively be used for the treatment of breast cancer is something that almost has been forgotten about, whereas the fear for estrogens remains. This paper reviews the use of estrogens for the treatment of breast cancer and identifies possible applications for the future.

Coelingh Bennink et al Maturitas 2017 (HDE paper)

Results Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men published in The Journal of Clinical Endocrinology & Metabolism

Luteinizing hormone–releasing hormone agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects. The published study with the fetal estrogen estetrol (E4) in healthy males shows promise as a safe and effective drug for use in prostate cancer.

A Dose-Escalating Study With the Fetal Estrogen JCEM 2018